A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Clinical trial NCT02675231 · COMPLETED

Trial details

NCT number: NCT02675231
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hormone Receptor Positive Breast Cancer HER-2 Positive Breast Cancer

Start date: 2016-05-23
Primary completion: 2019-04-08
Enrollment: 237

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.